new rheumatologist survey indic rinvoq trend ahead expect
remain overweight rate share highlight herein new rheumatologist
survey data indic rinvoq uptak appear track meaning ahead
expect specif doc see rinvoq meaning differenti versu
jak famou halo also appear work rheumatologist
explicitli cite abbv stewardship drug key reason prescrib
quantit also struck robust current uptak measur share project
think portend meaning upsid near-term rinvoq estim rinvoq
larg take back seat skyrizi key growth driver mind investor
speak see feedback welcom sourc upsid come quarter
final someth write home ra highlight herein result new
survey rheumatologist field partner spherix global insight
specif focu launch metric rinvoq realli first meaning new
approv space sinc olumi june approv think feedback
key walk detail feedback qualit quantit
rinvoq decidedli posit
percept rinvoq strong notabl xeljanz still enjoy support
rheum given drug commerci histori doc indic rinvoq
prefer jak one prescrib cite safeti efficaci breadth
data key advantag xeljanz find remark rinvoq
approv august
halo also work indic xeljanz entrench
exist fulli doc indic would earli rinvoq adopt
abbvi involv term report sale contact appear abbv
rheumatolog focu rinvoq rival humira effort final
compar prior two ra launch olumi kevzara unaid awar
brand familiar initi user base head shoulder
share project portend meaning upsid rais estim target
month post launch note rinvoq regist patient share howev
ask delin recent script doc give rinvoq share ask project
share month rheum indic rinvoq share grow paper
feedback equat revenu comparison consensu full
year model feedback verbatim rais
ww rinvoq estim vs
consensu respect continu model
beat pjc vs consensu like chanc rinvoq upsid
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
spherix
remain overweight rate share highlight herein new rheumatologist survey data
indic rinvoq uptak appear track meaning ahead expect
specif doc see rinvoq meaning differenti versu jak
famou halo also appear work rheumatologist explicitli cite abbv
stewardship drug key reason prescrib quantit also struck
robust current uptak measur share project think portend meaning upsid
near-term rinvoq estim rinvoq larg take back seat skyrizi key growth
driver mind investor speak see feedback welcom sourc
upsid come quarter
partner spherix global insight latest ra survey includ feedback high-volum
us-bas rheumatologist octob elig particip survey
rheumatologist must practic year least ra patient
manag spend least profession time clinic practic see patient
survey rheumatologist manag averag ra patient mean ra patient
captur survey
herein mostli focu feedback ra survey also supplement
select feedback ankylos spondyl non-radiograph axial
spondyloarthr survey rheumatologist field one week ra
survey octob particip survey rheumatologist must
practic year spend least profession time clinic practic see
patient requir manag least patient though dont focu as-
specif feedback note rheumatologist captur survey manag averag
ra patient believ feedback compani percept market trend
worth includ
page
two month mid-august approv rinvoq alreadi rheumatologist top jak
choic limit one jak inhibitor fulli half would choos rinvoq would choos xeljanz
would choos olumi find prefer rinvoq remark particularli
consid xeljanz years-long lead time market rheum cite advantag
inde rheum chose xeljanz top choic frequent cite extens
experi familiar rheum chose rinvoq top choic cite host
driver includ qd dose select safeti profil head-to-head superior data
percept
rinvoq strong
question much advantag think xeljanz statu first jak market subsequ jak
page
work
continu held extrem high regard rheumatologist evidenc compani
percept feedback survey across board beat drug
manufactur rheumatologist percept commit clinic research patient support
program support practic rheumatolog commun knowledg sale rep
categori rheum chose top-perform compani
gener repres distant second choic
favor view halo translat directli rinvoq adopt one-third
rheum ra survey indic simpli manufactur rinvoq
like earli adopt brand see exhibit said agre
statu third jak market disadvantag brand view make earli
statu prefer jak inhibitor impress also highlight feedback
indic perceiv safeti advantag rinvoq doc disagre xeljanz safer
rinvoq doubl proport agre xeljanz safer relat
one-third agre pathway best benefit/risk ratio
rheum view rinvoq interchang xeljanz olumi much larger
share respect say theyr interchang
question compani among list would say associ follow
question top barrier hold back/wil hold back prescrib rinvoq practic pleas select appli indic primari barrier rinvoq
user rinvoq non-us extent think follow jak inhibitor clinic interchang
page
abbv
effort rival
abbv rinvoq market effort full forc rival humira show
use spherix data time field octob two-third
rheumatologist contact rinvoq rep past month second humira
contact past month contact rate prior week show similar trend
rinvoq humira product one-week contact rate
xeljanz
question last time contact sale repres follow brand
page
good
effect abbv commerci market prowess strikingli appar
compar launch metric rinvoq recent ra lunch similar point launch
unaid awar rinvoq stand well ahead olumi kevzara
awar respect immedi launch brand familiar also
much higher rinvoq well half survey rheumatologist indic high
familiar compar olumi kevzara
earli ra launch benchmark awar familiar
question awar new product indic rheumatoid arthriti recent fda approv expect approv next year kevzara
notabl ra survey field seven day survey octob
point proport rheum report rinvoq rep contact within prior week
increas proport report contact within past month rose
see exhibit refer similar point olumi launch
rheum report sale rep contact within prior week within prior month
similar point kevzara launch rheum report kevzara rep contact within
prior week within prior month
question last time contact sale repres follow brand
page
market effort translat directli prescript rinvoq user base alreadi
dwarf olumi user base point launch exce kevzara
interestingli prescrib depth also somewhat higher rinvoq user prescrib
averag patient vs olumi kevzara respect compar point
launch
earli ra launch benchmark user base initi
question consid ra patient treat biologics/jak pleas alloc percent patient follow brand
page
rinvoq share stood rheum project grow next six
month user base expect expand greatli note
higher olumi project user base though doc expect olumi gain
share next six month rinvoq adopt project come
partli expens xeljanz whose share repres declin
current share
humira share project fall enbrel project declin
howev would note brand particularli humira
proven fairli resili recent quarter spherix ra report see previou note
humira share project declin next six month enbrel
share project fall next six month clearli project share
eros hasnt born updat remain seen equal
resili come quarter said brand asid rinvoq olumi
project see growth next six month kevzara increas
cimzia
ra current month brand share
question consid ra patient biologics/jak pleas alloc percent patient follow brand total equal
month ra patient treat biologics/jak anticip brand alloc refer current brand usag provid
indic anticip infliximab share month project ra patient treat infliximab percent anticip brand
percent anticip biosimilar
page
share bode well
rinvoq humira
show recent ra prescript share rheumatologist ask alloc
last five biologic/jak prescript ra patient highlight trend humira
rinvoq recent script share humira actual higher overal brand share
indic us retain hold set like chanc remain
resili come quarter
rinvoq recent script share approach xeljanz fell also far
exce olumi fell view give credibl rinvoq six-month
share project notabl rheum report rinvoq patient receiv sampl
start revenu impact rinvoq patient start like felt immedi
question think last five new prescript wrote biolog jak ra patient pleas alloc indic last five new prescript
xeljanz mani receiv sampl xeljanz start therapi indic last five new prescript olumi mani receiv
sampl olumi start therapi indic last five new prescript rinvoq mani receiv sampl rinvoq start therapi
page
rapidli increas
current rinvoq prescrib ask mani ra patient initi rinvoq
mani expect initi next three month feedback also bode well
launch current user prescrib rinvoq median patient mean
expect doubl number rinvoq patient median initi
next three month variabl expect initi almost one-fifth
current prescrib expect initi patient rinvoq next three month bring
mean number expect initi
rinvoq ra patient initi intend initi current user
question indic biologic-tr ra patient rinvoq exactli mani ra patient
prescrib rinvoq number ra patient plan initi rinvoq next three month current user
among rheumatologist hadnt prescrib rinvoq late-octob
half expect prescrib within next three month within next month
month feedback impli rinvoq user base exceed within three
page
time rinvoq adopt non-us
question anticip prescrib rinvoq ra patient
page
littl one-third rheum cite insur cost issu primari barrier
prevent prescrib rinvoq one-fifth cite comfort
agent main barrier use cite concern drug long-term safeti
barrier use unexpect given drug recent launch dig
rinvoq access trend
rinvoq main barrier use
respond
question top barrier hold back/wil hold back prescrib rinvoq practice/
promisingli mani rinvoq prescrib describ drug manag care approv
process quick easi slow difficult though doc
person experi describ processs speed difficulti moder exhibit
major rheum gener report prior author proof dmard
failur one tnf requir approv rel report
proof failur two tnf requir
question scale pleas rate manag care approv process rinvoq use ra follow requir manag care approv rinvoq
page
shown exhibit rinvoq prescrib report close rinvoq patient
secur insur coverag one-third treat patient access
program though recal three-quart rinvoq patient receiv sampl start exhibit
dynam watch launch progress
question patient initi rinvoq mani
page
note script data
show weekli iqvia script data rinvoq dont believ repres full
pictur rinvoq demand trend paid script captur iqvia script go
accredo abbv free good program captur impact reliabl
script data particularli consid rinvoq prescrib indic three-quart
patient start sampl
upsid rais
rinvoq market share project impli signific upsid estim
consensu plug market share us ra model yield quarterli revenu
far exce previou rinvoq us ra revenu estim
actual exce previou rinvoq revenu estim likewis exce
consensu estim
mind heavi sampl dynam point launch experi doc
frequent overestim quickli new therapi gain market share rais
rinvoq estim -- much feedback impli exhibit model
revenu assum rinvoq exit us ra market share
well shi share project continu model us ra share hit
time-frame said rheumatologist project play think rinvoq
could surpris upsid estim consensu
page
increas rinvoq estim bring ep estim
along partial laps discount period bring price target
stay consist valuat methodolog appli multipl
non-gaap ep estim discount back
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit shaqe
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
